A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Status:
Recruiting
Trial end date:
2022-11-28
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and
safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring
specific HER2 activating mutations regardless of tumor histology. The target population are
patients who have progressed following prior treatment or who have no satisfactory
alternative treatment options, including approved second line therapies in the specific tumor
type. Pre-specified HER2 mutations will be locally assessed using NGS tests or alternative
methods. Prior HER2 targeting therapy is permitted